Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Amortizatization of Intangibles (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 15 years of Amortizatization of Intangibles data on record, last reported at $70000.0 in Q3 2025.

  • For Q3 2025, Amortizatization of Intangibles fell 9.09% year-over-year to $70000.0; the TTM value through Sep 2025 reached $277000.0, down 10.36%, while the annual FY2020 figure was $650000.0, 301.86% up from the prior year.
  • Amortizatization of Intangibles reached $70000.0 in Q3 2025 per NWBO's latest filing, up from $66000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $93000.0 in Q1 2021 and bottomed at $56000.0 in Q2 2021.
  • Average Amortizatization of Intangibles over 5 years is $70461.5, with a median of $70000.0 recorded in 2025.
  • The widest YoY moves for Amortizatization of Intangibles: up 16.25% in 2021, down 33.72% in 2021.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $57000.0 in 2021, then rose by 10.53% to $63000.0 in 2022, then rose by 15.87% to $73000.0 in 2023, then grew by 5.48% to $77000.0 in 2024, then decreased by 9.09% to $70000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortizatization of Intangibles were $70000.0 in Q3 2025, $66000.0 in Q2 2025, and $64000.0 in Q1 2025.